US20150224095A1 - Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells - Google Patents
Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells Download PDFInfo
- Publication number
- US20150224095A1 US20150224095A1 US14/694,697 US201514694697A US2015224095A1 US 20150224095 A1 US20150224095 A1 US 20150224095A1 US 201514694697 A US201514694697 A US 201514694697A US 2015224095 A1 US2015224095 A1 US 2015224095A1
- Authority
- US
- United States
- Prior art keywords
- cells
- peptide
- receptor antagonist
- concentration
- wells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title claims abstract description 57
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title claims abstract description 57
- 239000002464 receptor antagonist Substances 0.000 title claims abstract description 35
- 229940044551 receptor antagonist Drugs 0.000 title claims abstract description 35
- 210000004881 tumor cell Anatomy 0.000 title claims description 24
- 230000006907 apoptotic process Effects 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims abstract description 14
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 11
- 206010018338 Glioma Diseases 0.000 claims abstract description 11
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 10
- 208000017604 Hodgkin disease Diseases 0.000 claims abstract description 9
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 201000001441 melanoma Diseases 0.000 claims abstract description 9
- 201000008968 osteosarcoma Diseases 0.000 claims abstract description 9
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims abstract description 9
- 208000011691 Burkitt lymphomas Diseases 0.000 claims abstract description 8
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims abstract description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 8
- 208000006168 Ewing Sarcoma Diseases 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 269
- FCDRFVCGMLUYPG-ROUUACIJSA-N (2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CO[C@@H]2[C@@H](NCCC2)C=2C=CC=CC=2)=C1 FCDRFVCGMLUYPG-ROUUACIJSA-N 0.000 claims description 138
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 230000035755 proliferation Effects 0.000 claims description 14
- 229960001372 aprepitant Drugs 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- XILNRORTJVDYRH-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC)N2C(=NN=N2)C(F)(F)F)=CC=CC=C1 XILNRORTJVDYRH-HKUYNNGSSA-N 0.000 claims description 5
- LDXQLWNPGRANTO-GOSISDBHSA-N (9r)-7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C([C@H](CN(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C1=O)C)CN(C(C2=NC=CC=C22)=O)C1=C2C1=CC=C(C)C=C1 LDXQLWNPGRANTO-GOSISDBHSA-N 0.000 claims description 5
- 210000004882 non-tumor cell Anatomy 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 3
- 208000005400 Synovial Cyst Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 208000021039 metastatic melanoma Diseases 0.000 claims description 3
- 229950005485 vofopitant Drugs 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- -1 3,5-bis(trifluoromethyl)phenyl Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 abstract description 8
- 239000003890 substance P antagonist Substances 0.000 abstract description 6
- 201000005296 lung carcinoma Diseases 0.000 abstract description 2
- 201000008275 breast carcinoma Diseases 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 44
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 43
- 230000001413 cellular effect Effects 0.000 description 35
- 239000005557 antagonist Substances 0.000 description 33
- 238000000034 method Methods 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 30
- 230000005764 inhibitory process Effects 0.000 description 23
- 230000004663 cell proliferation Effects 0.000 description 22
- 230000010261 cell growth Effects 0.000 description 17
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 12
- 102100024304 Protachykinin-1 Human genes 0.000 description 12
- 101800003906 Substance P Proteins 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 238000000692 Student's t-test Methods 0.000 description 11
- 238000001516 cell proliferation assay Methods 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000007619 statistical method Methods 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 102000004142 Trypsin Human genes 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 9
- 239000012588 trypsin Substances 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000017095 negative regulation of cell growth Effects 0.000 description 6
- 102000003141 Tachykinin Human genes 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 108060008037 tachykinin Proteins 0.000 description 4
- 101100057139 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PMR1 gene Proteins 0.000 description 3
- 101100165674 Schizosaccharomyces pombe (strain 972 / ATCC 24843) bsd1 gene Proteins 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 208000010400 APUDoma Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000002466 tachykinin receptor agonist Substances 0.000 description 1
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention involves the use of P substance antagonists, specifically non-peptide NK1 receptor antagonists, in the treatment of human cancers, explicitly on melanoma, neuroblastoma, glioma, Hodgkin's-KM-H2 lymphoma, lymphoblastic leukemia, Rhabdomyosarcoma, breast cancer, Burkitt's lymphoma, lung cancer, Ewing's sarcoma and human osteosarcoma.
- P substance antagonists specifically non-peptide NK1 receptor antagonists
- Substance P is a natural undecapeptide from the Tachykinins family and is used for its rapid stimulant action on smooth muscle tissue. More specifically, Substance P is an active pharmacological neuropeptide that is produced in mammals. It was originally isolated in the intestine and possesses an amino acid sequence that has been described by D. F. Veber, in the patent U.S. Pat. No. 4,680,283. The implication of Substance P, like in other Tachykinins, is seen in the physiopathology in a large number of illnesses that are well demonstrated in the bibliography.
- Substance P receptor is a member of the super family of G-protein-coupled receptors.
- the neuropeptide receptor of Substance P (NK-1) is well distributed in the nervous system of mammals (especially in the cerebrum and spinal cord) the circulatory system and in the peripheral tissues (especially in the duodenum and in the jejunum) and is involved in the regulation of diverse biological processes.
- the central and peripheral action of the Tachykinins in mammals have been associated with various inflammatory conditions such as migraines, rheumatoid arthritis, asthma, and intestinal inflammatory disease, as well as in the mediation of nauseous reflexes, and the regulation of CNS central nervous system disorders such as Parkinson's disease.
- various inflammatory conditions such as migraines, rheumatoid arthritis, asthma, and intestinal inflammatory disease, as well as in the mediation of nauseous reflexes, and the regulation of CNS central nervous system disorders such as Parkinson's disease.
- Neurosci. Res. 1996, 7, 187-214
- anxiety Can. J. Phys.; 1997, 612-621
- depression Science, 1998, 281, 1640-1645.
- U.S. Pat. No. 5,972,938 describes a method for the treatment of a psychoimmunological disorder or psychomotor by way of the administration of an NK1 receptor antagonist.
- NK-1 antagonist receptors can be used in the treatment of breaking certain drug addition habits such as those associated with opiates, nicotine as well as in the reduction of abuse and abstinence from the drugs.
- the article in Life Sci.; 2000, 67(9), 985-1001 describes the Astrocytes express functional receptors for various neurotransmitters in the reception of Substance P.
- the cerebral tumors of malignant glials derived from Astrocytes unchain under the action of the Tachykinins mediating the NK-1 receptors in the secretion of soluble mediators that augment the speed of reproliferation. Consequently, the selective antagonists of NK-1 can be very useful therapeutic agents in the treatment of malignant gliomas and for the treatment of cancer.
- the patent EP 773026 states the use of non-peptide NK1 receptor antagonists in the treatment of breast cancer, particularly in the treatment of small lung cancers in APUdoma, neuro endocrinic tumors, and small extra lung carcinomas.
- NK1 receptors in the treatment of adenocarcinoma is described, most specifically in prostatic carcinomas.
- Giardina, G.; Gagliardi S. and Martinelli M. review the most recent patents about the NK1, NK2 and NK3 receptors in “Antagonists at the neurokinin receptors-Recent patent literature” (IDrugs 2003; 6(8): 758-772).
- the authors describe the action of the molecules of the most important world producers with a specific indication of the most noteworthy possible applications being used in the treatment of: depression, inflammation, anxiety, vomiting, Ulcerative colitis and other illnesses.
- the objective of the current invention is the use of non-peptide NK1 receptor antagonists and Substance P for the production of apoptosis in breast cancer tumors.
- the tumor cells that the antagonists act on present a number of NK1 receptors that is superior to those in non tumor cells, composed of between 400% and 500% of the normal number of non tumor cells.
- the tumor cells that the antagonists act on are selected from the group consisting of:
- glioma cells human breast cancer cells
- Acute lymphoblastic leukemia B cells Acute lymphoblastic leukemia B cells
- Acute lymphoblastic leukemia T cells Acute lymphoblastic leukemia T cells
- neuroblastoma cells astrocytoma cells
- the tumor cells related to human melanoma on which the current antagonists act in cell lines are COLO 858 [ICLC, Interlab Cell Line Collection—CBA—Génova), MEL HO [DSMZ, Deutsche Sammlung von Mikroorganismen and Zellkulturen] and COLO 679 [DSMZ].
- the tumor cells related to the human glioma and the human neuroblastoma to which the antagonists act on in cell lines are the GAMG [DSMZ] and SKN-BE (2) [ICLC].
- the tumor cells related to lymphoblastic leukemia which the current antagonists act on are human lymphoblastic leukemia cells B SD1 [DSMZ] and human lymphoblastic leukemia cells TBE-13 [DSMZ].
- the tumor cells related to Burkitt's lymphoma on which the antagonists act in cell lines are CA-46 [DSMZ].
- the tumor cells related to Hodgkin's lymphoma on which the antagonists act are KM-H2 [DSMZ].
- the tumor cells related to human rhabdomyosarcoma on which the antagonists act in a cell line form are A-204 [DSMZ].
- the tumor cells related to small human lung cancer cells on which the antagonists act in a cell line are COLO-677 [DSMZ].
- the tumor cells related to human breast cancer on which the antagonists act in a cell line are MT-3 [DSMZ].
- the tumor cells related to Ewing's sarcoma on which the current antagonists act in a cell line are MHH-ES-1 [DSMZ].
- the tumor cells related to human osteosarcoma on which the current antagonists act in a cell line are MG-63 [ICLC].
- One of the antagonists used is (2S,3S) 3- ⁇ [3,5-Bis(trifluoromethyl)phenyl]methoxy ⁇ -2-phenylpiperidine, commercially known as L-733060 (Sigma-Aldrich) and used in concentrations composed of between 5 ⁇ M and 50 ⁇ M.
- the other objective on the current invention is the use of the non-peptide NK1 receptor and Substance P antagonists, such as the aforementioned indicators in the creation of a pharmaceutical composition for the treatment of cancer.
- NK1 receptor and Substance P antagonists to induce apoptosis in tumor cells of mammals, characterized in that the tumor cells that the antagonists act on are selected among: invasive primary and invasive malignant melanomas; metastatic melanoma cells; cells localized in ganglion lymph nodes; glioma cells—human breast cancer cells; Acute lymphoblastic leukemia B cells; Acute lymphoblastic leukemia T cells; primary neuroblastoma cells; astrocytoma cells; Burkitt's lymphoma cells; Hodgkin's lymphoma cells; rhabdomyosarcoma cells; small lung cancer cells; Ewing's sarcoma cells; and osteosarcoma cells.
- the antagonists act, for example, on tumor cells related to any of:
- the antagonist L-733060 may be used in concentrations of between 5 ⁇ M and 50 ⁇ M.
- a antagonist that is selected among some of the following compounds: vofopitant 6 GR-205171 (Pfizer); eziopitant 6 CJ-11974 (Pfizer); CP-122721 (Pfizer); Aprepitant 6 MK 869 6 L-754030 (MSD); L-758298 (MSD); TAK-637 (Takeda/Abbot); GW597599 (GSK); GW679769 (GSK);
- non-peptide NK1 receptor and Substance P antagonists for the development of a pharmaceutical compound for the treatment of cancer.
- FIGS. 1A and 1B variation in the time of the concentration of the cells SKN-BE (2) to growing concentrations of L-733,060 ( 1 A) in the cellular growth inhibition of SKN-BE (2) ( 1 B).
- FIGS. 2A and 2B variation in the time of the concentration of the cells COLO 858 to growing concentrations of L-733,060 ( 2 A) in the cellular growth inhibition of COLO 858 ( 2 B).
- FIGS. 3A and 3B variation in the time of the concentration of the cells MEL HO to growing concentrations of L-733,060 ( 3 A) in the cellular growth inhibition of MEL HO ( 3 B).
- FIGS. 4A and 4B variation in the time of the concentration of the cells COLO 679 to growing concentrations of L-733,060 ( 4 A) in the cellular growth inhibition of COLO 679 ( 4 B).
- FIG. 5 variation in the time of the concentration of the cells SD1 to growing concentrations of L-733,060 ( 5 A) in the cellular growth inhibition of SD1 ( 5 B).
- FIGS. 6A and 6B variation in the time of the concentration of the cells KM-H2 to growing concentrations of L-733,060 ( 6 A) in the cellular growth inhibition of KM-H2 ( 6 B).
- FIGS. 7A and 7B variation in the time of the concentration of the cells MT-3 to growing concentrations of L-733,060 ( 7 A) in the cellular growth inhibition of MT-3 ( 7 B).
- FIGS. 8A and 8B variation in the time of the concentration of the cells MHH-ES-1 to growing concentrations of L-733,060 ( 8 A) in the cellular growth inhibition of MHH-ES-1 ( 8 B).
- FIG. 9 variation in the time of the concentration of the cells MG-63 to growing concentrations of L-733,060 ( 9 A) in the cellular growth inhibition of MG-63 ( 9 B).
- FIGS. 10A and 10B variation in the time of the concentration of the cells GAMG to growing concentrations of L-733,060 ( 10 A) in the cellular growth inhibition of GAMG ( 10 B).
- This line was maintained in a culture of RPMI 1640 (GIBCO-BRL) supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- the cell line was cultivated in 75 ml flasks (Falcon, Germany). Half was refreshed every two days and the cells were treated with trypsin (0.05% and 0.02% EDTA without Ca 2+ and Mg 2+ ) every six days. The cells were incubated at a temperature of 37 C in humidified (95% air/5% CO 2 ).
- NK1 receptor antagonists 2S,3S)3-([3,5Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 20 ⁇ M) were studied with the objective of determining the IC 50 .
- DMSO dimethyl sulfoxide
- Methods of cellular proliferation During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T 0 , T 1 and T 2 .
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and the wells were read 90 minutes later.
- T 1 and T 2 were treated with different concentrations of (2.5 ⁇ M to 20 ⁇ M) of L-733,060 and were incubated during a period of 30 hrs. (first cellular duplication) (T 1 ) and 72 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by testing the optical density, being directly proportional to the number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated on an adequate curve based on the parameters.
- Results The results shown in FIG. 1A represent the variation in time of the concentration of cells SKN-BE (2) at growing concentrations of L-733,060.
- FIG. 1B shows the percentage of inhibition of cellular growth of SKNBE (2) (at 30 hrs. and 72 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 20 ⁇ M), at the first and second duplication times of the incubation.
- the non-continuous lines represent IC 50 at 30 and 72 hrs.
- the points on the graph represent the average value/typical deviation.
- COLO 858 ICLC Interlab Cell LineCollection—CBA—Génova
- MEL HO MEL HO
- COLO 679 DSMZDeutsche Sammlung von Mikroorganismen and Zellkulturen
- the cell lines were cultivated in 75 ml flasks (Falcon, Germany).
- the NK1 receptor antagonist, (2S,3S)3-([3,5Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine (L-733,060)(Sigma-Aldrich, U. K.) was dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. With the objective of determining the IC 50 , different concentrations (2.5 ⁇ M to 50 ⁇ M) were studied.
- the cellular proliferation was evaluated using the MTS method 1344,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], according to the instructions of use established by (Cet) Titer 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 1 and T 2 were treated with different concentrations (2.5 ⁇ M to 50 ⁇ M) of L-733,060 and were incubated during a varying period in cell lines.
- Line MEL HO 24 hrs. (cellular duplication) (T 1 ) and 48 hrs. (second cellular duplication) (T 2 ).
- Line COLO 679 30 hrs. (cellular duplication) (T 1 ) and 72 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 90 min before reading the plate samples with the (TECAN Spectra Classic) 492 nm.
- the quantity of MTS reagent was determined by measurement of the optical density, being directly proportional to the number of live cells.
- Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentrations to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated on a curve suited to the parameters.
- Results The results are shown in FIGS. 2A , 2 B (COLO 858), FIGS. 3A and 3B (MEL HO) and FIGS. 4A and 4B (COLO 679).
- FIG. 2A represents the variation in the time of the concentration of cells COLO 858 to growing concentrations of L-733,060 (from 2.5 to 20 ⁇ M).
- FIG. 3A represents the variation in the time of the concentration of cells MEL HO to growing concentrations of L-733,060 (from 10 to 30 ⁇ M).
- FIG. 4A represents the variation in the time of the concentration of cells COLO 679 to growing concentrations of L-733,060 (from 20 to 50 ⁇ M).
- FIG. 2B the inhibition of cellular growth is shown from COLO 858 (at 48 and 96 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 20 ⁇ M).
- the discontinuous lines represent the IC 50 for 48 and 96 hrs.
- the points on the graph represent the value of the average value/typical deviation.
- FIG. 3B the inhibition of cellular growth is shown from MEL HO (at 24 and 48 hrs.) after the addition of growing concentrations of L-733,060 (10, 20, 25, and 30 ⁇ M).
- the discontinuous lines represent the IC 50 for 24 and 48 hrs.
- the points on the graph represent the average value/typical deviation.
- FIG. 4B the inhibition of cellular growth is shown from COLO 679 (at 30 and 72 hrs. after the addition of growing concentrations of L-733,060 (20, 30, 40, and 50 ⁇ M).
- the discontinuous lines represent the IC 50 for 30 and 72 hrs.
- the points on the graph represent the average value/typical deviation.
- the cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO 2 ).
- NK1 receptors Treatment with antagonist NK1 receptors: The solutions of the antagonist NK1 receptors (2S,3S) 3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 25 ⁇ M) were studied in order to determine the IC 50 .
- DMSO dimethyl sulfoxide
- the cellular proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and they were read 90 minutes later.
- T 1 and T 2 were treated with different concentrations (2.5 ⁇ M to 25 ⁇ M) of L-733,060 and were incubated during a period of 30 hrs. (cellular duplication) (T 1 ) and 72 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 180 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated with a curve suited to the parameters.
- Results The results shown in FIG. 5 represents the variation in time of the concentration of cells BSD1 to growing concentrations of L-733,060.
- the inhibition of cell growth BSD1 is represented (at 30 and 72 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 25 ⁇ M). The percentage of the inhibition for the first and second time of the duplication of the incubation is shown.
- the discontinuous lines represent the IC 50 at 30 and 72 hrs.
- the points on the graph represent the average value/typical deviation.
- This cell line was maintained in a culture of RPMI 1640 and supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- the cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with trypsin (0.05% and 0.02% EDTA without Ca 2+ and Mg 2+ ) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO 2 ).
- NK1 receptor antagonists Treatment with NK1 receptor antagonists: The solutions of the antagonist NK1 receptors (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 25 ⁇ M) were studied to determine the IC 50 .
- DMSO dimethyl sulfoxide
- the cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- Method of Cellular Proliferation The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates called T 0 , T 1 and T 2 .
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and they were read 90 minutes later.
- T 1 and T 2 were treated with different concentrations (2.5 ⁇ M to 25 ⁇ M) of L-733,060 and were incubated during a period of 35 hrs. (cellular duplication) (T 1 ) and 72 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (ICso) with L-733,060 was calculated on a curve suited to the parameters.
- This cell line was maintained in a culture of RPMI 1640 and supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- the cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO 2 ).
- NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060)(Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 20 ⁇ M) were studied to determine the IC 50 .
- DMSO dimethyl sulfoxide
- the cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both, T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and they were read 90 minutes later.
- T 1 and T 2 were treated with different concentrations of (2.5 ⁇ M to 20 ⁇ M) of L-733,060 and were incubated during a period of 48 hrs. (cellular duplication) (T 1 ) and 96 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 180 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated on a curve suited to the parameters.
- the data obtained was evaluated using the Student's T Test, with a significance level of p ⁇ 0.05.
- Results The results shown in FIG. 6A represent the variation in the time of the concentration of the cells KM-H2 with growing concentrations of L-733,060.
- FIG. 6B the inhibition of cell growth KM-H2 is represented (at 48 and 96 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 20 ⁇ M). The percentage of the inhibition for the first and second time of the duplication of the incubation.
- the discontinuous lines represent the IC 50 at 48 and 96 hrs.
- the points on the graph represent the average value/typical deviation.
- a cell line related to human rhabdomyosarcoma A-204 (DSMZ) were used.
- This cell line was maintained in a culture of Mc—Co— supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- NK1 receptors Treatment with antagonist NK1 receptors: The solutions of the antagonist NK1 receptors (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060)(Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 25 ⁇ M) were studied to determine the IC 50 .
- DMSO dimethyl sulfoxide
- the cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and were read 90 minutes later.
- T 1 and T 2 were treated with different concentrations (2.5 ⁇ M to 20 ⁇ M) of L-733,060 and were incubated during a period of 36 hrs. (first cellular duplication) (T 1 ) and 72 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by testing the optical density, being directly proportional to the number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated on an adequate curve based on the parameters.
- a cell line related to small cell lung cancer COLO-677 was used. This cell line was maintained in a culture of RPMI 1640 supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- the cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with Trypsin (0.05% and 0.02% EDTA without Ca 2+ and Mg 2+ ) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- NK1 receptors Treatment with antagonist NK1 receptors: The solutions of the antagonist NK1 receptors (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060)(Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 25 ⁇ M) were studied to determine the IC 50 .
- DMSO dimethyl sulfoxide
- the cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- Method of Cellular Proliferation During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T 0 , T 1 and T 2 .
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and they were read 90 minutes later.
- T 1 and T 2 were treated with different concentrations (5 ⁇ M to 20 ⁇ M) of L-733,060 and were incubated during a period of 40 hrs. (first cellular duplication) (T 1 ) and 96 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by testing the optical density, being directly proportional to the number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated on an adequate curve based on the parameters.
- a cell line related to human breast cancer MT-3 (DSMZ) was used. This cell line was maintained in a culture of RPMI 1640 supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- the cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with Trypsin (0.05% and 0.02% EDTA without Ca 2+ and Mg 2+ ) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 20 ⁇ M) were studied to determine the IC 50 .
- DMSO dimethyl sulfoxide
- the cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- Method of Cellular Proliferation During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T 0 , T 1 and T 2 .
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and they were read 90 minutes later.
- T 1 and T 2 were treated with different concentrations (2.5 ⁇ M to 20 ⁇ M) of L-733,060 and were incubated during a period of 30 hrs. (first cellular duplication) (T 1 ) and 72 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated on a curve suited to the parameters.
- Results represent the variation in the time of the concentration of cells MT-3 at growing concentrations of L-733,060.
- the inhibition of cell growth MT-3 is represented (at 30 and 72 hrs.) after the addition of increasing concentrations of L-733,060 (2.5, 5, 10, 20 ⁇ M).
- the percentage of the inhibition for the first and second time in the duplication of the incubation The discontinuous lines represent the IC 50 at 30 and 72 hrs.
- the points on the graph represent the average value/typical deviation.
- a cell lines related to Ewing's human sarcoma MHH-ES-1 was used. This cell line was maintained in a culture of RPMI 1640 supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- the cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with Trypsin (0.05% and 0.02% EDTA without Ca 2+ and Mg 2+ ) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 25 ⁇ M) were studied to determine the IC 50 .
- DMSO dimethyl sulfoxide
- the cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- Method of Cellular Proliferation During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T 0 , T 1 and T 2 .
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and they were read 90 minutes later.
- T 1 and T 2 were treated with different concentrations (5 ⁇ M to 20 ⁇ M) of L-733,060 and were incubated during a period of 30 hrs. (first cellular duplication) (T 1 ) and 72 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated on a curve suited to the parameters.
- Results The results shown in FIG. 8A represent the variation in the time of the concentration of cells MHH-ES-1 at growing concentrations of L-733,060.
- FIG. 8B the inhibition of cell growth MHH-ES-1 is represented (at 30 and 72 hrs.) after the addition of growing concentrations of L-733,060 (5, 10, 15, 20, ⁇ M). The percentage of the inhibition for the first and second time of the duplication of the incubation.
- the discontinuous lines represent the IC 50 at 30 and 72 hrs.
- the points on the graph represent the average value/typical deviation.
- a cell line related to human osteosarcoma MG-63 (ICLC) was used.
- This cell line was maintained in a culture of MEN supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- the cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with Trypsin (0.05% and 0.02% EDTA without Ca 2+ and Mg 2+ ) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 25 ⁇ M) were studied to determine the IC 50 .
- DMSO dimethyl sulfoxide
- the cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- Method of Cellular Proliferation During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T 0 , T 1 and T 2 .
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and they were read 90 minutes after.
- T 1 and T 2 were treated with different concentrations (2.5 ⁇ M to 25 ⁇ M) of L-733,060 and were incubated during a period of 30 hrs. (one cellular duplication) (T 1 ) and 72 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by optical density, being directly proportional to the number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated on a curve suited to the parameters.
- Results The results shown in FIG. 9A represent the variation in the time of the concentration of cells at growing concentrations of L-733,060.
- FIG. 9B the inhibition of cell growth MG-63 is represented (at 30 and 72 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 20 and 25 ⁇ M). The percentage of the inhibition for the first and second time of the duplication of the incubation.
- the discontinuous lines represent the IC 50 at 30 and 72 hrs.
- the points on the graph represent the average value/typical deviation.
- DSMZ human glioma GAMG
- This cell line was maintained in a culture of MEN supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- the cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with trypsin (0.05% and 0.02% EDTA without Ca 2+ and Mg 2+ ) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 ⁇ M to 25 ⁇ M) were studied to determine the IC 50 .
- DMSO dimethyl sulfoxide
- the cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA).
- Method of Cellular Proliferation During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T 0 , T 1 and T 2 .
- T 0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (10 4 cells/0.1 ml) were termed control wells. Both T 1 and T 2 included white wells (0 cells/0.1 ml), control wells (10 4 cells/0.1 ml) and control wells treated with L-733,060.
- T 0 20 ⁇ l of MTS reagent was immediately added to the wells and they were read 90 minutes later.
- T 1 and T 2 were treated with different concentrations (2.5 ⁇ M to 25 ⁇ M) of L-733,060 and were incubated during a period of 48 hrs. (first cellular duplication) (T 1 ) and 96 hrs. (second cellular duplication) (T 2 ).
- MTS reagent 20 ⁇ l was added to each well (T 1 , T 2 ) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm.
- the quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells.
- Each plate white, control, and control treated with different concentrations of L-733,060 was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC 50 ) with L-733,060 was calculated on a curve suited to the parameters.
- Results The results shown in FIG. 10A represent the variation in the time of the concentration of cells at growing concentrations of L-733,060.
- FIG. 10B the inhibition of cell growth GAMG is represented (at 48 and 96 hrs.) after the addition of growing concentrations of L-733,060 (10, 15, 20 and 25 ⁇ M). The percentage of the inhibition for the first and second time of the duplication of the incubation.
- the discontinuous lined represent the IC 50 at 30 and 72 hrs.
- the points on the graph represent the average value/typical deviation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Substance P antagonists and, in particular, non-peptidic NK1 receptor antagonists are useful for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma.
Description
- The present application is a Division of U.S. Ser. No. 11/721,256, filed Sep. 16, 2008, which is a National Phase conversion under 35 U.S.C. §371 of PCT/ES2005/000068, filed Feb. 10, 2005, which claims benefit of priority from Spanish Application No. ES200400424, filed Feb. 11, 2004, the disclosure of which are each incorporated herein by reference. PCT International Application was published in the Spanish language.
- The invention involves the use of P substance antagonists, specifically non-peptide NK1 receptor antagonists, in the treatment of human cancers, explicitly on melanoma, neuroblastoma, glioma, Hodgkin's-KM-H2 lymphoma, lymphoblastic leukemia, Rhabdomyosarcoma, breast cancer, Burkitt's lymphoma, lung cancer, Ewing's sarcoma and human osteosarcoma.
- Substance P is a natural undecapeptide from the Tachykinins family and is used for its rapid stimulant action on smooth muscle tissue. More specifically, Substance P is an active pharmacological neuropeptide that is produced in mammals. It was originally isolated in the intestine and possesses an amino acid sequence that has been described by D. F. Veber, in the patent U.S. Pat. No. 4,680,283. The implication of Substance P, like in other Tachykinins, is seen in the physiopathology in a large number of illnesses that are well demonstrated in the bibliography.
- Substance P receptor is a member of the super family of G-protein-coupled receptors. The neuropeptide receptor of Substance P (NK-1) is well distributed in the nervous system of mammals (especially in the cerebrum and spinal cord) the circulatory system and in the peripheral tissues (especially in the duodenum and in the jejunum) and is involved in the regulation of diverse biological processes.
- The central and peripheral action of the Tachykinins in mammals have been associated with various inflammatory conditions such as migraines, rheumatoid arthritis, asthma, and intestinal inflammatory disease, as well as in the mediation of nauseous reflexes, and the regulation of CNS central nervous system disorders such as Parkinson's disease. (Neurosci. Res., 1996, 7, 187-214), anxiety (Can. J. Phys.; 1997, 612-621) and depression (Science, 1998, 281, 1640-1645).
- In the article titled “Tachykinin Receptor and Tachykinin Receptor Antagonists”, by J. Auton, in Pharmacol.; 1993, 13, 23-93, the use of antagonists of Substance P have been evidenced in the treatment of headaches, especially migraines, Alzheimer's disease, multiple sclerosis, attenuation of the syndrome in the absence of opiates, cardio vascular changes, edemas, such as those provoked by burns, in chronic inflammatory illnesses like rheumatoid arthritis, asthma, hyperactive bronchials, and other respiratory illnesses including allergic rhinitis, etc.
- Also, U.S. Pat. No. 5,972,938 describes a method for the treatment of a psychoimmunological disorder or psychomotor by way of the administration of an NK1 receptor antagonist.
- The article published in Nature, 2000, 405 (6783), 180-183 details the activity in rats lacking NK-1 receptors and shows a decrease in the beneficial effects of morphine. Consequently, the NK-1 antagonist receptors can be used in the treatment of breaking certain drug addition habits such as those associated with opiates, nicotine as well as in the reduction of abuse and abstinence from the drugs.
- The article in Life Sci.; 2000, 67(9), 985-1001 describes the Astrocytes express functional receptors for various neurotransmitters in the reception of Substance P. The cerebral tumors of malignant glials derived from Astrocytes unchain under the action of the Tachykinins mediating the NK-1 receptors in the secretion of soluble mediators that augment the speed of reproliferation. Consequently, the selective antagonists of NK-1 can be very useful therapeutic agents in the treatment of malignant gliomas and for the treatment of cancer.
- Additionally, the New Journal of Medicine, 1999, 340, 190-195, states that the use of a selective NK1 receptor induces the reduction of vomiting by employing cisplatin.
- In the article published in the International Journal of Cancer by Antal Orosz et al. 1995, 60, 82-87, the use of diverse peptide antagonists in Substance P (SP) is described in the inhibition of the proliferation of lung cancer cells. (Ex. in designated cells NCI-H69). Equally as important is the article published in Cancer Research, 1994, 54, 3602-3610, describing another antagonist of Substance P (SP) as well as other peptides capable of the inhibition of the growth of various in-vitro lines in cancerous lung cells (ex. Designated cells NCI-H510, NCI-H345, and SHP-77).
- The patent EP 773026 (Pfizer) states the use of non-peptide NK1 receptor antagonists in the treatment of breast cancer, particularly in the treatment of small lung cancers in APUdoma, neuro endocrinic tumors, and small extra lung carcinomas.
- Additionally in the WO 2001001922 patent the use of NK1 receptors in the treatment of adenocarcinoma is described, most specifically in prostatic carcinomas. Giardina, G.; Gagliardi S. and Martinelli M. review the most recent patents about the NK1, NK2 and NK3 receptors in “Antagonists at the neurokinin receptors-Recent patent literature” (IDrugs 2003; 6(8): 758-772). The authors describe the action of the molecules of the most important world producers with a specific indication of the most noteworthy possible applications being used in the treatment of: depression, inflammation, anxiety, vomiting, Ulcerative colitis and other illnesses.
- The objective of the current invention is the use of non-peptide NK1 receptor antagonists and Substance P for the production of apoptosis in breast cancer tumors. The tumor cells that the antagonists act on present a number of NK1 receptors that is superior to those in non tumor cells, composed of between 400% and 500% of the normal number of non tumor cells.
- The tumor cells that the antagonists act on are selected from the group consisting of:
- invasive primary and invasive malignant melanomas;
- metastatic melanoma cells;
- cells localized in ganglion lymph nodes—glioma cells—human breast cancer cells;
- Acute lymphoblastic leukemia B cells;
- Acute lymphoblastic leukemia T cells;
- primary neuroblastoma cells—astrocytoma cells;
- Burkitt's lymphoma cells;
- Hodgkin's lymphoma cells;
- Rhabdomyosarcoma cells;
- small lung cancer cells;
- Ewing's sarcoma cells; and
- osteosarcoma cells.
- They indicated the continuation in specific cells acted upon by the non-peptide NK1 receptor antagonists and substance P.
- The tumor cells related to human melanoma on which the current antagonists act in cell lines are COLO 858 [ICLC, Interlab Cell Line Collection—CBA—Génova), MEL HO [DSMZ, Deutsche Sammlung von Mikroorganismen and Zellkulturen] and COLO 679 [DSMZ].
- The tumor cells related to the human glioma and the human neuroblastoma to which the antagonists act on in cell lines are the GAMG [DSMZ] and SKN-BE (2) [ICLC].
- The tumor cells related to lymphoblastic leukemia which the current antagonists act on are human lymphoblastic leukemia cells B SD1 [DSMZ] and human lymphoblastic leukemia cells TBE-13 [DSMZ]. The tumor cells related to Burkitt's lymphoma on which the antagonists act in cell lines are CA-46 [DSMZ]. The tumor cells related to Hodgkin's lymphoma on which the antagonists act are KM-H2 [DSMZ]. The tumor cells related to human rhabdomyosarcoma on which the antagonists act in a cell line form are A-204 [DSMZ]. The tumor cells related to small human lung cancer cells on which the antagonists act in a cell line are COLO-677 [DSMZ]. The tumor cells related to human breast cancer on which the antagonists act in a cell line are MT-3 [DSMZ].
- The tumor cells related to Ewing's sarcoma on which the current antagonists act in a cell line are MHH-ES-1 [DSMZ].
- The tumor cells related to human osteosarcoma on which the current antagonists act in a cell line are MG-63 [ICLC].
- One of the antagonists used is (2S,3S) 3-{[3,5-Bis(trifluoromethyl)phenyl]methoxy}-2-phenylpiperidine, commercially known as L-733060 (Sigma-Aldrich) and used in concentrations composed of between 5 μM and 50 μM.
- Other compounds of antagonist non-peptide receptors NK1 and Substance P that can be used include:
- vofopitant6GR-205171 (Pfizer);
- eziopitant 6 CJ-11974 (Pfizer);
- CP-122721 (Pfizer);
- Aprepitant 6 MK 869 6 L-754030 (MSD);
- L-758298 (MSD);
- TAK-637 (Takeda/Abbot);
- GW597599 (GSK);
- GW679769 (GSK); and
- R673 (Roche).
- Lastly, the other objective on the current invention is the use of the non-peptide NK1 receptor and Substance P antagonists, such as the aforementioned indicators in the creation of a pharmaceutical composition for the treatment of cancer.
- It is therefore an object to provide for the use of non-peptide NK1 receptor and Substance P antagonists to induce apoptosis in tumor cells of mammals.
- It is also an object to provide for the use of non-peptide NK1 receptor and Substance P antagonists to induce apoptosis in tumor cells of mammals characterized in that the tumor cells that the antagonists act on present between 400% and 500% of the number of NK1 receptors as compared to those present in non-tumor cells.
- It is a further object to provide for the use of non-peptide NK1 receptor and Substance P antagonists to induce apoptosis in tumor cells of mammals, characterized in that the tumor cells that the antagonists act on are selected among: invasive primary and invasive malignant melanomas; metastatic melanoma cells; cells localized in ganglion lymph nodes; glioma cells—human breast cancer cells; Acute lymphoblastic leukemia B cells; Acute lymphoblastic leukemia T cells; primary neuroblastoma cells; astrocytoma cells; Burkitt's lymphoma cells; Hodgkin's lymphoma cells; rhabdomyosarcoma cells; small lung cancer cells; Ewing's sarcoma cells; and osteosarcoma cells.
- The antagonists act, for example, on tumor cells related to any of:
- human melanoma cell lines COLO 858 [ICLC, Interlab Cell Line Collection—CBA—Génova), MEL HO [DSMZ, Deutsche Sammlung von Mikroorganismen undZelikulturen] and COLO 679 [DSMZ];
- human glioma and neuroblastoma cell lines GAMG [DSMZ] and SKN-BE (2) [ICLC];
- lymphoblastic leukemia cell lines B SD1 [DSMZ] and TBE-13 [DSMZ];
- Burkitt's lymphoma cell line CA-46 [DSMZ];
- Hodgkin's lymphoma cell line KM-H2 [DSMZ];
- rhabdomyosarcoma cell line A-204 [DSMZ];
- small cell lung cancer cell line COLO-677 [DSMZ];
- breast cancer cell line MT-3 [DSMZ];
- Ewing's sarcoma cell line MHH-ES-1 [DSMZ]; and
- osteosarcoma cell line MG-63[ICLC].
- It is a further object to induce apoptosis in tumor cells of mammals using of the antagonist (2S,3S) 3-{[3,5-Bis(trifluoromethyl)phenyl]methoxy}-2-phenylpiperidine, commercially known as L-733060 (Sigma-Aldrich). The antagonist L-733060 may be used in concentrations of between 5 μM and 50 μM.
- It is a still further object to induce apoptosis in tumor cells of mammals by uses of a antagonist that is selected among some of the following compounds: vofopitant 6 GR-205171 (Pfizer); eziopitant 6 CJ-11974 (Pfizer); CP-122721 (Pfizer); Aprepitant 6 MK 869 6 L-754030 (MSD); L-758298 (MSD); TAK-637 (Takeda/Abbot); GW597599 (GSK); GW679769 (GSK); and R673 (Roche).
- It is also an object to use non-peptide NK1 receptor and Substance P antagonists for the development of a pharmaceutical compound for the treatment of cancer.
-
FIGS. 1A and 1B : variation in the time of the concentration of the cells SKN-BE (2) to growing concentrations of L-733,060 (1A) in the cellular growth inhibition of SKN-BE (2) (1B). -
FIGS. 2A and 2B : variation in the time of the concentration of thecells COLO 858 to growing concentrations of L-733,060 (2A) in the cellular growth inhibition of COLO 858 (2B). -
FIGS. 3A and 3B : variation in the time of the concentration of the cells MEL HO to growing concentrations of L-733,060 (3A) in the cellular growth inhibition of MEL HO (3B). -
FIGS. 4A and 4B : variation in the time of the concentration of thecells COLO 679 to growing concentrations of L-733,060 (4A) in the cellular growth inhibition of COLO 679 (4B). -
FIG. 5 : variation in the time of the concentration of the cells SD1 to growing concentrations of L-733,060 (5A) in the cellular growth inhibition of SD1 (5B). -
FIGS. 6A and 6B : variation in the time of the concentration of the cells KM-H2 to growing concentrations of L-733,060 (6A) in the cellular growth inhibition of KM-H2 (6B). -
FIGS. 7A and 7B : variation in the time of the concentration of the cells MT-3 to growing concentrations of L-733,060 (7A) in the cellular growth inhibition of MT-3 (7B). -
FIGS. 8A and 8B : variation in the time of the concentration of the cells MHH-ES-1 to growing concentrations of L-733,060 (8A) in the cellular growth inhibition of MHH-ES-1 (8B). -
FIG. 9 : variation in the time of the concentration of the cells MG-63 to growing concentrations of L-733,060 (9A) in the cellular growth inhibition of MG-63 (9B). -
FIGS. 10A and 10B : variation in the time of the concentration of the cells GAMG to growing concentrations of L-733,060 (10A) in the cellular growth inhibition of GAMG (10B). - In addition, a detailed explanation of how the activity was carried out was based on the current invention of each tested in cell lines. The following examples are provided only in order to illustrate the invention and thus they should not be construed as limiting.
- A Cell line of human neuroblastoma SKN-BE (2)(ICLC Interlab Cell Line Collection—CBA—Génova) was used.
- This line was maintained in a culture of RPMI 1640 (GIBCO-BRL) supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half was refreshed every two days and the cells were treated with trypsin (0.05% and 0.02% EDTA without Ca2+ and Mg2+) every six days. The cells were incubated at a temperature of 37 C in humidified (95% air/5% CO2).
- Treatment with the NK1 receptor antagonists: The solutions of antagonist NK1 receptors (2S,3S)3-([3,5Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 20 μM) were studied with the objective of determining the IC50.
- The proliferation of cells was tested using the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium]method, following the instructions established by (Cet)
Titer 96 Aqueous One Solution Cell Proliferation Assay, Promega, (USA). - Methods of cellular proliferation: During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and the wells were read 90 minutes later. T1 and T2 were treated with different concentrations of (2.5 μM to 20 μM) of L-733,060 and were incubated during a period of 30 hrs. (first cellular duplication) (T1) and 72 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by testing the optical density, being directly proportional to the number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated on an adequate curve based on the parameters.
- Statistical Analysis: The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: The results shown in
FIG. 1A represent the variation in time of the concentration of cells SKN-BE (2) at growing concentrations of L-733,060. -
FIG. 1B shows the percentage of inhibition of cellular growth of SKNBE (2) (at 30 hrs. and 72 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 20 μM), at the first and second duplication times of the incubation. The non-continuous lines represent IC50 at 30 and 72 hrs. The points on the graph represent the average value/typical deviation. - Cell lines related to melanomas COLO 858 (ICLC Interlab Cell LineCollection—CBA—Génova), MEL HO and COLO 679 (DSMZDeutsche Sammlung von Mikroorganismen and Zellkulturen) were used.
- These cell lines were maintained in a culture of RPMI 1640 (GIBCOBRL) supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC, the ICLC and the DSMZ.
- The cell lines were cultivated in 75 ml flasks (Falcon, Germany).
- Half was renewed every two days and the cells were treated with trypsin (0.05% and 0.02% EDTA without Ca2+ and Mg2+) every six days. The cells were incubated at 37 C in humidified (95% air/5% CO2).
- The NK1 receptor antagonist, (2S,3S)3-([3,5Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine (L-733,060)(Sigma-Aldrich, U. K.) was dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. With the objective of determining the IC50, different concentrations (2.5 μM to 50 μM) were studied.
- The cellular proliferation was evaluated using the MTS method 1344,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], according to the instructions of use established by (Cet)
Titer 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Cellular Proliferation Method: During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- 20 μl of MTS reagent was immediately added to the T0 wells and they were read 90 minutes after. T1 and T2 were treated with different concentrations (2.5 μM to 50 μM) of L-733,060 and were incubated during a varying period in cell lines.
- Line COLO 858: 48 h. (first cellular duplication) (T1) and 96 hrs. (second cellular duplication) (T2).
- Line MEL HO: 24 hrs. (cellular duplication) (T1) and 48 hrs. (second cellular duplication) (T2).
- Line COLO 679: 30 hrs. (cellular duplication) (T1) and 72 hrs. (second cellular duplication) (T2).
- To study the cellular proliferation, 20 μl of MTS reagent was added to each well (T1, T2) 90 min before reading the plate samples with the (TECAN Spectra Classic) 492 nm. The quantity of MTS reagent was determined by measurement of the optical density, being directly proportional to the number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentrations to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated on a curve suited to the parameters.
- Statistical Analysis: The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: The results are shown in
FIGS. 2A , 2B (COLO 858),FIGS. 3A and 3B (MEL HO) andFIGS. 4A and 4B (COLO 679). -
FIG. 2A represents the variation in the time of the concentration ofcells COLO 858 to growing concentrations of L-733,060 (from 2.5 to 20 μM). -
FIG. 3A represents the variation in the time of the concentration of cells MEL HO to growing concentrations of L-733,060 (from 10 to 30 μM). -
FIG. 4A represents the variation in the time of the concentration ofcells COLO 679 to growing concentrations of L-733,060 (from 20 to 50 μM). - In
FIG. 2B , the inhibition of cellular growth is shown from COLO 858 (at 48 and 96 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 20 μM). The discontinuous lines represent the IC50 for 48 and 96 hrs. The points on the graph represent the value of the average value/typical deviation. - In
FIG. 3B the inhibition of cellular growth is shown from MEL HO (at 24 and 48 hrs.) after the addition of growing concentrations of L-733,060 (10, 20, 25, and 30 μM). The discontinuous lines represent the IC50 for 24 and 48 hrs. The points on the graph represent the average value/typical deviation. - In
FIG. 4B the inhibition of cellular growth is shown from COLO 679 (at 30 and 72 hrs. after the addition of growing concentrations of L-733,060 (20, 30, 40, and 50 μM). The discontinuous lines represent the IC50 for 30 and 72 hrs. The points on the graph represent the average value/typical deviation. - Cell lines related to human lymphoblastic leukemia were used, BSD1 (DSMZ) and T BE-13 (DSMZ).
- These cell lines were maintained in a culture of 1640 supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- Treatment with antagonist NK1 receptors: The solutions of the antagonist NK1 receptors (2S,3S) 3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 25 μM) were studied in order to determine the IC50.
- The cellular proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (
CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Method of Cellular Proliferation: The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and they were read 90 minutes later. T1 and T2 were treated with different concentrations (2.5 μM to 25 μM) of L-733,060 and were incubated during a period of 30 hrs. (cellular duplication) (T1) and 72 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 180 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated with a curve suited to the parameters.
- Statistical Analysis: The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: The results shown in
FIG. 5 represents the variation in time of the concentration of cells BSD1 to growing concentrations of L-733,060. - In
FIG. 5 , the inhibition of cell growth BSD1 is represented (at 30 and 72 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 25 μM). The percentage of the inhibition for the first and second time of the duplication of the incubation is shown. The discontinuous lines represent the IC50 at 30 and 72 hrs. The points on the graph represent the average value/typical deviation. - Linear cells related to human Burkitt's lymphoma were used with CA-46 (DSMZ).
- This cell line was maintained in a culture of RPMI 1640 and supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with trypsin (0.05% and 0.02% EDTA without Ca2+ and Mg2+) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- Treatment with NK1 receptor antagonists: The solutions of the antagonist NK1 receptors (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 25 μM) were studied to determine the IC50.
- The cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (
CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Method of Cellular Proliferation: The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates called T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and they were read 90 minutes later. T1 and T2 were treated with different concentrations (2.5 μM to 25 μM) of L-733,060 and were incubated during a period of 35 hrs. (cellular duplication) (T1) and 72 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (ICso) with L-733,060 was calculated on a curve suited to the parameters.
- Statistical Analysis: The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: At the highest concentrations, inhibition in cellular growth was produced and at the maximum dose, apoptosis.
- A cell line related to human Hodgkin's lymphoma.KM-H2 (DSMZ) was used.
- This cell line was maintained in a culture of RPMI 1640 and supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- Treatment with NK1 receptor antagonists: The solutions of the NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060)(Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 20 μM) were studied to determine the IC50.
- The cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (
CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Method of Cellular Proliferation: The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both, T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and they were read 90 minutes later. T1 and T2 were treated with different concentrations of (2.5 μM to 20 μM) of L-733,060 and were incubated during a period of 48 hrs. (cellular duplication) (T1) and 96 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 180 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated on a curve suited to the parameters.
- The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: The results shown in
FIG. 6A represent the variation in the time of the concentration of the cells KM-H2 with growing concentrations of L-733,060. - In
FIG. 6B the inhibition of cell growth KM-H2 is represented (at 48 and 96 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 20 μM). The percentage of the inhibition for the first and second time of the duplication of the incubation. The discontinuous lines represent the IC50 at 48 and 96 hrs. The points on the graph represent the average value/typical deviation. - A cell line related to human rhabdomyosarcoma A-204 (DSMZ) were used.
- This cell line was maintained in a culture of Mc—Co— supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with Trypsin (0.05% and 0.02% EDTA without Ca2+ and Mg2+) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- Treatment with antagonist NK1 receptors: The solutions of the antagonist NK1 receptors (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060)(Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 25 μM) were studied to determine the IC50.
- The cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (
CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Method of Cellular Proliferation: During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and were read 90 minutes later. T1 and T2 were treated with different concentrations (2.5 μM to 20 μM) of L-733,060 and were incubated during a period of 36 hrs. (first cellular duplication) (T1) and 72 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by testing the optical density, being directly proportional to the number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated on an adequate curve based on the parameters.
- Statistical Analysis: The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: Cellular growth is inhibited at the highest concentrations and at the maximum dose, apoptosis.
- A cell line related to small cell lung cancer COLO-677 (DSMZ) was used. This cell line was maintained in a culture of RPMI 1640 supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with Trypsin (0.05% and 0.02% EDTA without Ca2+ and Mg2+) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- Treatment with antagonist NK1 receptors: The solutions of the antagonist NK1 receptors (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060)(Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 25 μM) were studied to determine the IC50.
- The cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (
CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Method of Cellular Proliferation: During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and they were read 90 minutes later. T1 and T2 were treated with different concentrations (5 μM to 20 μM) of L-733,060 and were incubated during a period of 40 hrs. (first cellular duplication) (T1) and 96 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by testing the optical density, being directly proportional to the number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated on an adequate curve based on the parameters.
- Statistical Analysis The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: Cellular growth is inhibited at the highest concentrations and at the maximum dose, apoptosis.
- A cell line related to human breast cancer MT-3 (DSMZ) was used. This cell line was maintained in a culture of RPMI 1640 supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with Trypsin (0.05% and 0.02% EDTA without Ca2+ and Mg2+) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- Treatment with NK1 receptor antagonists: The solutions of the NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U. K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 20 μM) were studied to determine the IC50.
- The cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (
CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Method of Cellular Proliferation: During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and they were read 90 minutes later. T1 and T2 were treated with different concentrations (2.5 μM to 20 μM) of L-733,060 and were incubated during a period of 30 hrs. (first cellular duplication) (T1) and 72 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated on a curve suited to the parameters.
- Statistical Analysis: The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: The results shown in
FIG. 7A represent the variation in the time of the concentration of cells MT-3 at growing concentrations of L-733,060. - In
FIG. 7B , the inhibition of cell growth MT-3 is represented (at 30 and 72 hrs.) after the addition of increasing concentrations of L-733,060 (2.5, 5, 10, 20 μM). The percentage of the inhibition for the first and second time in the duplication of the incubation. The discontinuous lines represent the IC50 at 30 and 72 hrs. The points on the graph represent the average value/typical deviation. - A cell lines related to Ewing's human sarcoma MHH-ES-1 (DSMZ) was used. This cell line was maintained in a culture of RPMI 1640 supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with Trypsin (0.05% and 0.02% EDTA without Ca2+ and Mg2+) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- Treatment with NK1 receptor antagonists The solutions of the NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 25 μM) were studied to determine the IC50.
- The cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (
CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Method of Cellular Proliferation: During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and they were read 90 minutes later. T1 and T2 were treated with different concentrations (5 μM to 20 μM) of L-733,060 and were incubated during a period of 30 hrs. (first cellular duplication) (T1) and 72 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated on a curve suited to the parameters.
- Statistical Analysis: The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: The results shown in
FIG. 8A represent the variation in the time of the concentration of cells MHH-ES-1 at growing concentrations of L-733,060. - In
FIG. 8B the inhibition of cell growth MHH-ES-1 is represented (at 30 and 72 hrs.) after the addition of growing concentrations of L-733,060 (5, 10, 15, 20, μM). The percentage of the inhibition for the first and second time of the duplication of the incubation. The discontinuous lines represent the IC50 at 30 and 72 hrs. The points on the graph represent the average value/typical deviation. - A cell line related to human osteosarcoma MG-63 (ICLC) was used.
- This cell line was maintained in a culture of MEN supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with Trypsin (0.05% and 0.02% EDTA without Ca2+ and Mg2+) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- Treatment with NK1 receptor antagonists: The solutions of the NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 25 μM) were studied to determine the IC50.
- The cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (
CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Method of Cellular Proliferation: During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and they were read 90 minutes after. T1 and T2 were treated with different concentrations (2.5 μM to 25 μM) of L-733,060 and were incubated during a period of 30 hrs. (one cellular duplication) (T1) and 72 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by optical density, being directly proportional to the number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated on a curve suited to the parameters.
- Statistical Analysis: The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: The results shown in
FIG. 9A represent the variation in the time of the concentration of cells at growing concentrations of L-733,060. - In
FIG. 9B the inhibition of cell growth MG-63 is represented (at 30 and 72 hrs.) after the addition of growing concentrations of L-733,060 (2.5, 5, 10, 20 and 25 μM). The percentage of the inhibition for the first and second time of the duplication of the incubation. The discontinuous lines represent the IC50 at 30 and 72 hrs. The points on the graph represent the average value/typical deviation. - A cell line related to human glioma GAMG (DSMZ) was used.
- This cell line was maintained in a culture of MEN supplemented with 10% fetal bovine serum according to the established cellular culture conditions of the ATCC.
- The cell line was cultivated in 75 ml flasks (Falcon, Germany). Half were renewed every two days and the cells were treated with trypsin (0.05% and 0.02% EDTA without Ca2+ and Mg2+) every six days. The cells were incubated at a temperature of 37° C. in humidified (95% air/5% CO2).
- Treatment with NK1 receptor antagonists: The solutions of the NK1 receptor antagonists (2S,3S)3-([3,5-Bis(trifluoromethyl)phenyl]methoxy)-2-phenylpiperidine, (L-733,060) (Sigma-Aldrich, U.K.) were dissolved in distilled water containing 0.2% dimethyl sulfoxide (DMSO) before treating the samples. Different concentrations of (2.5 μM to 25 μM) were studied to determine the IC50.
- The cell proliferation was evaluated using the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfophenyl)-2H-tetrazolium], following the manufacturer's instructions for use (
CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, USA). - Method of Cellular Proliferation: During the experiment, the cultivated cells were broken apart every 4-5 days by way of trypsinization and to test the cell viability the trypan blue method was used. The cells were quantified and cultured in plates of 96 wells each. Each experiment included three plates termed T0, T1 and T2.
- T0 contained wells without cells (0 cells/0.1 ml) termed white wells and wells that contained cells (104 cells/0.1 ml) were termed control wells. Both T1 and T2 included white wells (0 cells/0.1 ml), control wells (104 cells/0.1 ml) and control wells treated with L-733,060.
- In T0, 20 μl of MTS reagent was immediately added to the wells and they were read 90 minutes later. T1 and T2 were treated with different concentrations (2.5 μM to 25 μM) of L-733,060 and were incubated during a period of 48 hrs. (first cellular duplication) (T1) and 96 hrs. (second cellular duplication) (T2).
- To study the proliferation of the cells, 20 μl of MTS reagent was added to each well (T1, T2) 90 min before reading the samples with the plate reader (TECAN Spectra Classic) at 492 nm. The quantity of MTS reagent was measured by optical density, being directly proportional in number of live cells. Each plate (white, control, and control treated with different concentrations of L-733,060) was performed in triplicate. The experiment was repeated on three different occasions. The concentration to inhibit fifty percent of the cells (IC50) with L-733,060 was calculated on a curve suited to the parameters.
- Statistical Analysis. The data obtained was evaluated using the Student's T Test, with a significance level of p<0.05.
- Results: The results shown in
FIG. 10A represent the variation in the time of the concentration of cells at growing concentrations of L-733,060. - In
FIG. 10B the inhibition of cell growth GAMG is represented (at 48 and 96 hrs.) after the addition of growing concentrations of L-733,060 (10, 15, 20 and 25 μM). The percentage of the inhibition for the first and second time of the duplication of the incubation. The discontinuous lined represent the IC50 at 30 and 72 hrs. The points on the graph represent the average value/typical deviation.
Claims (20)
1. A pharmaceutical composition for the treatment of cancer in humans, comprising an effective amount of a non-peptide NK1 receptor antagonist, selected from the group consisting of aprepitant (MK 869 or L-754,030 (MSD)), L-758,298 (MSD), L-733,060 (MSD/Sigma-Aldrich), TAK-637 (Takeda/Abbot), GW597,599 (GSK), GW679,769 (GSK), and R673 (Roche), to achieve a concentration of between 5-50 μM at cancer cells to be treated.
2. The pharmaceutical composition according to claim 1 , wherein the effective amount is sufficient to achieve a concentration of at least 20 μM.
3. A pharmaceutical composition for treating a human having cancel by inducing apoptosis in human cancer cells expressing at least 400% greater NK1 receptors than corresponding non-tumor cells of the same cell type, comprising an effective amount of a non-peptide NK1 receptor antagonist to achieve a concentration of at least an IC50 for proliferation of the human cancer cells.
4. The pharmaceutical composition according to claim 3 , wherein the effective amount is sufficient to achieve a concentration of at least 5 μM.
5. The pharmaceutical composition according to claim 3 , wherein the effective amount is sufficient to achieve a concentration of at least 20 μM.
6. The pharmaceutical composition according to claim 3 , comprising an effective amount of the non-peptide NK1 receptor antagonist to achieve a concentration of between about 5-50 μM.
7. The pharmaceutical composition according to claim 3 , wherein the non-peptide NK1 receptor antagonist is selected from the group consisting of:
L-733,060 (2S,3S) 3-{[3,5-bis(trifluoromethyl)phenyl]methoxy}-2-phenylpiperidine (MSD/Sigma-Aldrich);
Vofopitant GR-205,171 (Pfizer);
eziopitant CJ-11974 (Pfizer);
CP-122,721 (Pfizer);
Aprepitant (MK 869) (L-754,030) (MSD) (5-[[(2R,3S)-2-[(1R)-I-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one);
L-758,298 (MSD);
TAK-637 (Takeda/Abbot);
GW597,599 (GSK);
GW679,769 (GSK); and
R673 (Roche).
8. The pharmaceutical composition according to claim 7 , wherein the non-peptide NK1 receptor antagonist comprises aprepitant.
9. The pharmaceutical composition according to claim 7 , wherein the non-peptide NK1 receptor antagonist comprises L-733,060.
10. The pharmaceutical composition according to claim 7 , wherein the non-peptide NK1 receptor antagonist comprises a 3,5-bis(trifluoromethyl)phenyl alkoxy ligand.
11. The pharmaceutical composition according to claim 7 , wherein the non-peptide NK1 receptor antagonist comprises at least one trifluoromethyl ligand.
12. A pharmaceutical formulation for treatment of a tumor in an animal, the tumor having tumor cells which have a number of NK1 receptors of at least 400% of normal cells of the same type, comprising a non-peptide NK1 receptor antagonist in an amount sufficient to achieve a concentration of between about 5-50 μM in the animal.
13. The pharmaceutical formulation according to claim 12 , comprising an effective amount of a non-peptide NK1 receptor antagonist to achieve a concentration of at least 20 μM.
14. The pharmaceutical formulation according to claim 12 , wherein the non-peptide NK1 receptor antagonist is selected from the group consisting of:
(2S,3S) 3-{[3,5-bis(trifluoromethyl)phenyl]methoxy}-2-phenylpiperidine L-733,060 (MSD/Sigma-Aldrich);
Vofopitant GR-205171 (Pfizer);
eziopitant CJ-11974 (Pfizer);
CP-122721 (Pfizer);
Aprepitant (MK 869) (L-754030) (MSD) (5-[[(2R,3S)-2-[(1R)-I-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one);
L-758298 (MSD);
TAK-637 (Takeda/Abbot);
GW597599 (GSK);
GW679769 (GSK); and
R673 (Roche).
15. The pharmaceutical formulation according to claim 14 , wherein the non-peptide NK1 receptor antagonist comprises aprepitant.
16. The pharmaceutical formulation according to claim 14 , wherein the non-peptide NK1 receptor antagonist comprises L-733,060.
17. The pharmaceutical formulation according to claim 14 , wherein the non-peptide NK1 receptor antagonist comprises a 3,5-bis(trifluoromethyl)phenyl alkoxy ligand.
18. The pharmaceutical formulation according to claim 14 , wherein the non-peptide NK1 receptor antagonist comprises at least one trifluoromethyl ligand.
19. The pharmaceutical formulation according to claim 12 , wherein the amount sufficient to achieve a concentration of between about 5-50 μM in the animal is in excess of an IC50 for proliferation of the tumor cells.
20. The pharmaceutical formulation according to claim 12 , wherein the tumor cells are selected from the group consisting of:
invasive primary and invasive malignant melanomas;
metastatic melanoma cells;
cells localized in ganglion lymph nodes;
glioma cells—human breast cancer cells;
Acute lymphoblastic leukemia B cells;
Acute lymphoblastic leukemia T cells;
primary neuroblastoma cells;
astrocytoma cells;
Burkitt's lymphoma cells;
Hodgkin's lymphoma cells;
Rhabdomyosarcoma cells;
small lung cancer cells;
Ewing's sarcoma cells; and osteosarcoma cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/694,697 US20150224095A1 (en) | 2004-02-11 | 2015-04-23 | Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200400424 | 2004-02-11 | ||
ES200400424A ES2246687B2 (en) | 2004-02-11 | 2004-02-11 | USE OF NON-PEPTIDIC ANTAGONISTS OF NK1 RECEPTORS FOR THE PRODUCTION OF APOPTOSIS IN TUMOR CELLS. |
PCT/ES2005/000068 WO2005077366A1 (en) | 2004-02-11 | 2005-02-10 | Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells |
US72125608A | 2008-09-16 | 2008-09-16 | |
US14/694,697 US20150224095A1 (en) | 2004-02-11 | 2015-04-23 | Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/721,256 Division US9867814B2 (en) | 2004-02-11 | 2005-02-10 | Use of non-peptidic NK1 receptor antagonists for the production of apoptosis in tumour cells |
PCT/ES2005/000068 Division WO2005077366A1 (en) | 2004-02-11 | 2005-02-10 | Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150224095A1 true US20150224095A1 (en) | 2015-08-13 |
Family
ID=34854896
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/721,256 Expired - Fee Related US9867814B2 (en) | 2004-02-11 | 2005-02-10 | Use of non-peptidic NK1 receptor antagonists for the production of apoptosis in tumour cells |
US14/694,697 Abandoned US20150224095A1 (en) | 2004-02-11 | 2015-04-23 | Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells |
US15/850,496 Abandoned US20180117027A1 (en) | 2004-02-11 | 2017-12-21 | Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells |
US16/438,695 Abandoned US20200054620A1 (en) | 2004-02-11 | 2019-06-12 | Use of Non-Peptidic NK1 Receptor Antagonists for the Production of Apoptosis in Tumour Cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/721,256 Expired - Fee Related US9867814B2 (en) | 2004-02-11 | 2005-02-10 | Use of non-peptidic NK1 receptor antagonists for the production of apoptosis in tumour cells |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/850,496 Abandoned US20180117027A1 (en) | 2004-02-11 | 2017-12-21 | Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells |
US16/438,695 Abandoned US20200054620A1 (en) | 2004-02-11 | 2019-06-12 | Use of Non-Peptidic NK1 Receptor Antagonists for the Production of Apoptosis in Tumour Cells |
Country Status (12)
Country | Link |
---|---|
US (4) | US9867814B2 (en) |
EP (2) | EP1803456B1 (en) |
AU (1) | AU2005211955B2 (en) |
CA (1) | CA2566315C (en) |
CY (1) | CY1116415T1 (en) |
DK (1) | DK1803456T5 (en) |
ES (2) | ES2246687B2 (en) |
HK (2) | HK1105886A1 (en) |
PL (1) | PL1803456T3 (en) |
PT (1) | PT1803456E (en) |
SI (1) | SI1803456T1 (en) |
WO (1) | WO2005077366A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024069344A1 (en) * | 2022-09-29 | 2024-04-04 | Keyzell Holding S.L. | Compositions for the treatment and prevention of cancer |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2246687B2 (en) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | USE OF NON-PEPTIDIC ANTAGONISTS OF NK1 RECEPTORS FOR THE PRODUCTION OF APOPTOSIS IN TUMOR CELLS. |
WO2009124756A1 (en) * | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Use of aprepitant and derivatives thereof for the treatment of cancer |
ES2376564B1 (en) * | 2010-08-12 | 2013-01-24 | Manuel Vicente Salinas Martín | USE OF ANTIBODIES AGAINST NK1, NK2 AND / OR NK3 RECEPTORS, TO PRODUCE APOPTOSIS IN TUMOR CELLS AND TO MODIFY STRAMA, IMMUNITY AND INTRA AND PERITUMORAL VASCULARIZATION, AS TREATMENT OF CANCER. |
WO2013087964A1 (en) | 2011-12-13 | 2013-06-20 | Servicio Andaluz De Salud | Use of agents that alter the peritumoral environment for the treatment of cancer |
ES2493693B1 (en) | 2013-02-11 | 2015-07-07 | Servicio Andaluz De Salud | Method to predict or predict the response of a human subject suffering from cancer to treatment with an NK1 receptor antagonist |
ES2541870B1 (en) | 2013-12-27 | 2016-05-12 | Servicio Andaluz De Salud | Use of NK1 non-peptide antagonists in a given dose for cancer treatment |
JP2017502973A (en) * | 2013-12-30 | 2017-01-26 | オンコプレフェント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Neurokinin-1 receptor antagonist for use in a method for preventing cancer |
WO2015166128A1 (en) * | 2014-04-29 | 2015-11-05 | Servicio Andaluz De Salud | Method for diagnosing and monitoring the presence of cancer in a human subject |
EP3171894B1 (en) * | 2014-07-24 | 2021-03-24 | Plus Vitech, S.L. | Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract |
ES2595442B1 (en) * | 2015-05-27 | 2017-10-04 | Consejo Superior De Investigaciones Cientificas (Csic) | ANTAGONISTS OF NK1 RECEPTORS DERIVED FROM CARBON HYDRATES, METHOD OF OBTAINING AND MEDICAL USE |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010034320A1 (en) * | 2000-01-18 | 2001-10-25 | Hans-Michael Brecht | NK1-receptor antagonists for treating restless legs syndrome |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680283A (en) | 1984-09-26 | 1987-07-14 | Merck & Co., Inc. | Analogs of substance P and eledoisin |
CA2106874A1 (en) * | 1991-04-22 | 1992-10-29 | Theofilus J. Visser | Method for detecting and localizing tissues having neurokinine 1 receptors |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
EP1462450B1 (en) | 1993-12-29 | 2007-06-13 | MERCK SHARP & DOHME LTD. | Substituted morpholine derivatives and their use as therapeutic agents |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
CA2189501A1 (en) * | 1995-11-06 | 1997-05-07 | Harry R. Howard | Nk-1 receptor antagonists for the treatment of cancer |
US6037340A (en) * | 1997-05-28 | 2000-03-14 | Cadus Pharmaceutical Corporation | Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
UA60365C2 (en) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal |
IT1306165B1 (en) * | 1999-07-05 | 2001-05-30 | Innova Ltd | USE OF INHIBITORS OF THE SUBSTANCE P FOR THE TREATMENT OF DENOCARCINOMAS. |
EA005409B1 (en) | 2000-04-10 | 2005-02-24 | Пфайзер Продактс Инк. | Benzoamide piperidine containing derivatives as substance p receptor antagonists |
DE60210760T2 (en) * | 2001-04-23 | 2006-11-23 | F. Hoffmann-La Roche Ag | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENEFICIAL PROSTATE HYPERPLASIA |
US6713490B2 (en) * | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
WO2005048942A2 (en) * | 2003-11-13 | 2005-06-02 | Pharmacia Corporation | Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent |
ES2246687B2 (en) | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | USE OF NON-PEPTIDIC ANTAGONISTS OF NK1 RECEPTORS FOR THE PRODUCTION OF APOPTOSIS IN TUMOR CELLS. |
JP2008536881A (en) | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Pharmaceutical formulation of GLP-1 molecule and antiemetic |
WO2009124756A1 (en) * | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Use of aprepitant and derivatives thereof for the treatment of cancer |
-
2004
- 2004-02-11 ES ES200400424A patent/ES2246687B2/en not_active Expired - Lifetime
-
2005
- 2005-02-10 AU AU2005211955A patent/AU2005211955B2/en not_active Ceased
- 2005-02-10 ES ES05708080.6T patent/ES2535184T3/en active Active
- 2005-02-10 PT PT05708080T patent/PT1803456E/en unknown
- 2005-02-10 EP EP05708080.6A patent/EP1803456B1/en not_active Not-in-force
- 2005-02-10 EP EP20140189674 patent/EP2842605A3/en not_active Withdrawn
- 2005-02-10 PL PL05708080T patent/PL1803456T3/en unknown
- 2005-02-10 WO PCT/ES2005/000068 patent/WO2005077366A1/en active Application Filing
- 2005-02-10 CA CA2566315A patent/CA2566315C/en not_active Expired - Fee Related
- 2005-02-10 SI SI200531939T patent/SI1803456T1/en unknown
- 2005-02-10 US US11/721,256 patent/US9867814B2/en not_active Expired - Fee Related
- 2005-02-10 DK DK05708080.6T patent/DK1803456T5/en active
-
2008
- 2008-01-03 HK HK08100056.3A patent/HK1105886A1/en not_active IP Right Cessation
-
2015
- 2015-02-26 CY CY20151100199T patent/CY1116415T1/en unknown
- 2015-03-18 HK HK15102803.6A patent/HK1208192A1/en unknown
- 2015-04-23 US US14/694,697 patent/US20150224095A1/en not_active Abandoned
-
2017
- 2017-12-21 US US15/850,496 patent/US20180117027A1/en not_active Abandoned
-
2019
- 2019-06-12 US US16/438,695 patent/US20200054620A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010034320A1 (en) * | 2000-01-18 | 2001-10-25 | Hans-Michael Brecht | NK1-receptor antagonists for treating restless legs syndrome |
Non-Patent Citations (5)
Title |
---|
, Cancer Network, NK-1 receptor antagonist benefits of standard antiemetic therapy, July 01, 2012. * |
Dermer (Bio/Technology, 1994, 12:320). * |
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4). * |
Gura (Science, v278, 1997, pp.1041-1042). * |
Rosso et al, The Scientific World Journal Volume 2012. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024069344A1 (en) * | 2022-09-29 | 2024-04-04 | Keyzell Holding S.L. | Compositions for the treatment and prevention of cancer |
Also Published As
Publication number | Publication date |
---|---|
US20200054620A1 (en) | 2020-02-20 |
SI1803456T1 (en) | 2015-05-29 |
EP1803456B1 (en) | 2014-11-26 |
HK1208192A1 (en) | 2016-02-26 |
HK1105886A1 (en) | 2008-02-29 |
CA2566315A1 (en) | 2005-08-25 |
AU2005211955B2 (en) | 2011-06-23 |
PT1803456E (en) | 2015-03-04 |
CY1116415T1 (en) | 2017-02-08 |
US9867814B2 (en) | 2018-01-16 |
WO2005077366A1 (en) | 2005-08-25 |
PL1803456T3 (en) | 2015-08-31 |
ES2246687B2 (en) | 2006-11-16 |
DK1803456T5 (en) | 2015-06-22 |
ES2535184T3 (en) | 2015-05-06 |
US20180117027A1 (en) | 2018-05-03 |
EP2842605A3 (en) | 2015-03-18 |
ES2246687A1 (en) | 2006-02-16 |
AU2005211955A1 (en) | 2005-08-25 |
DK1803456T3 (en) | 2015-03-02 |
CA2566315C (en) | 2013-08-27 |
US20090012086A1 (en) | 2009-01-08 |
EP1803456A1 (en) | 2007-07-04 |
WO2005077366B1 (en) | 2005-09-15 |
EP2842605A2 (en) | 2015-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150224095A1 (en) | Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells | |
US6162805A (en) | Use of an NK-1 receptor antagonist and an SSRI for treating obesity | |
CN100398106C (en) | Use of nk-1 receptor antagonists against benign prostatic hyperplasia | |
EP2073808A2 (en) | New method for the treatment of inflammatory diseases | |
JP2011254820A (en) | Inhibitor of cellular niacinamide mononucleotide formation and use of the same in cancer therapy | |
RU2324484C2 (en) | Antagonists of metbotropic glutamate receptor 5 (mglur5) and methods of prevention and treatment of gastroesophageal reflux (options) | |
US20170165240A1 (en) | New strategies for treating melanoma | |
EA001779B1 (en) | Thrapeutic treatment for vegf related diseases | |
US20040077661A1 (en) | Treatment of tuberous sclerosis associated neoplasms | |
TW201217361A (en) | Method of treating abnormal cell growth | |
JP2006508933A (en) | 5-HT1B / 1D receptor agonists for the treatment of headaches resulting from administration of endothelin receptor antagonists | |
US20140221385A1 (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
US6576638B1 (en) | Use of substance P antagonists in the treatment of the adenocarcinomas | |
JP3663202B2 (en) | Therapeutic use | |
OA11231A (en) | Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer | |
US20200121689A1 (en) | Use of non-peptide nk1 antagonists in a predetermined dose for the treatment of cancer | |
JP2008143871A (en) | Use of nonpeptidic nk1 receptor antagonist inducing tumor apoptosis | |
CA2612333C (en) | Inhibition of osteolytic lesions by src kinase inhibitors | |
Nakada et al. | In vitro contractile effects of neurokinin receptor blockade in the human ureter | |
AU2007203079B2 (en) | N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4- [1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide as an anticancer agent | |
Naylor | Pharmacology of serotonin and its receptors | |
Roffman et al. | Use of antipsychotic medicationin chemotherapy-induced nausea and vomiting | |
Sorbera et al. | Cediranib | |
WO2002002116A2 (en) | Therapeutic treatment of cancer with a protein kinase c inhibitor | |
JPH0827029A (en) | New medicine use of 5ht1 agonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NK-1 IP LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANTAGONISTA ENEKAUNO, S.L.;REEL/FRAME:039148/0622 Effective date: 20160628 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |